Traditional means to identify and treat arterial disease are hampered by their inability to localize atheroma components. Novel targeted acoustic, highlighting, and delivery agents, such as liposomes, may overcome these problems. Liposomes are phospholipid vesicles enclosing an aqueous space. We have developed a unique methodology that, by process and composition, makes these liposomes echogenic. This formulation allows modification for antibody conjugation and therapeutic drug/gene incorporation. Work by this group has demonstrated that these formulations can incorporate therapeutics and deliver drugs and genes to cells, while retaining their echogenic properties. The addition of therapeutic ultrasound has an added unique effect on these echogenic liposomes by increasing cellular delivery. Our principal aim is to develop a model carrier and a technique that has the ability to incorporate a therapeutic with delivery to a target structure while retaining the therapeutic's effects. To this end, we will;a) develop optimal therapeutic echogenic immunoliposomes;b) develop optimal ultrasound parameters for therapeutic delivery of loaded ELIP and c) determine the efficacy of our therapeutic ELIP in slowing/stabilizing atheroma progression. We will use 3 novel therapeutics (rosiglitazone)anti- inflammatory;(bevacizumab) anti-angiogenesis;and (eNOS) anti-inflammatory gene. Our long term goals would be to deliver the therapeutic loaded ELIP simultaneously with ultrasound exposure, in patients, to trigger drug or gene delivery and enhance uptake in targeted vascular beds. By focusing our experiments in this direction, we would then be able to transition our techniques into the clinical setting to allow investigators to apply more directed therapy to improve physiologic cardiovascular flow.
This proposal seeks to develop a stable formulation (echogenic immunoliposomes) that has the ability to incorporate a therapeutic with delivery to a target structure while retaining the therapeutic's effect.
|Bader, Kenneth B; Haworth, Kevin J; Maxwell, Adam D et al. (2018) Post Hoc Analysis of Passive Cavitation Imaging for Classification of Histotripsy-Induced Liquefaction in Vitro. IEEE Trans Med Imaging 37:106-115|
|Miao, Yi-Feng; Peng, Tao; Moody, Melanie R et al. (2018) Delivery of xenon-containing echogenic liposomes inhibits early brain injury following subarachnoid hemorrhage. Sci Rep 8:450|
|Haworth, Kevin J; Bader, Kenneth B; Rich, Kyle T et al. (2017) Quantitative Frequency-Domain Passive Cavitation Imaging. IEEE Trans Ultrason Ferroelectr Freq Control 64:177-191|
|Klegerman, Melvin E; Moody, Melanie R; Hurling, Jermaine R et al. (2017) Gas chromatography/mass spectrometry measurement of xenon in gas-loaded liposomes for neuroprotective applications. Rapid Commun Mass Spectrom 31:1-8|
|Haworth, Kevin J; Raymond, Jason L; Radhakrishnan, Kirthi et al. (2016) Trans-Stent B-Mode Ultrasound and Passive Cavitation Imaging. Ultrasound Med Biol 42:518-27|
|Raymond, Jason L; Luan, Ying; Peng, Tao et al. (2016) Loss of gas from echogenic liposomes exposed to pulsed ultrasound. Phys Med Biol 61:8321-8339|
|Sutton, J T; Haworth, K J; Shanmukhappa, S K et al. (2016) Delivery of bevacizumab to atheromatous porcine carotid tissue using echogenic liposomes. Drug Deliv 23:3594-3605|
|Klegerman, Melvin E; Naji, Ali K; Haworth, Kevin J et al. (2016) Ultrasound-enhanced bevacizumab release from echogenic liposomes for inhibition of atheroma progression. J Liposome Res 26:47-56|
|Haworth, Kevin J; Raymond, Jason L; Radhakrishnan, Kirthi et al. (2016) Erratum to: ""Trans-stent B-mode Ultrasound and Passive Cavitation Imaging"" in Ultrasound Med Biol 2016;42(2):518-527. Ultrasound Med Biol 42:1244|
|Raymond, Jason L; Luan, Ying; van Rooij, Tom et al. (2015) Impulse response method for characterization of echogenic liposomes. J Acoust Soc Am 137:1693-703|
Showing the most recent 10 out of 57 publications